Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
NEWTOWN, Pa., Nov. 08, 2017 -- Helius Medical Technologies, Inc. (TSX:HSM), (OTCQB:HSDT) ("Helius" or the "Company"), a medical technology company focused on neurological wellness, announced today that it will report the results of its registrational trial investigating the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS™) for the treatment of chronic balance deficits due to mild-to-moderate Traumatic Brain Injury (TBI) by press release to be issued on Thursday, November 9, 2017 at 6:00 AM ET. The Company also plans to report results from a long-term clinical trial of the PoNS Therapy for the treatment of symptoms due to mild- to moderate TBI, performed at the University of Wisconsin-Madison.
Philippe Deschamps, the president and chief executive officer of Helius, will provide a presentation of the data, along with a company update, on Thursday, November 9, 2017 at 8:00 AM ET via webcast at http://www.wsw.com/webcast/cc/hsdt. Interested parties may also listen to the presentation by calling 1 (866) 939-3921 (US Toll Free) or 1 (678) 302-3550 (US Toll). Please use confirmation number 45986789. An archived copy of the webcast will be available at www.heliusmedical.com and http://www.wsw.com/webcast/cc/hsdt .
About PoNS™ Therapy
The Portable Neuromodulation Stimulator (PoNS™) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS™ Therapy combines the use of the device with physical therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate traumatic brain injury.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. Helius intends to file for FDA clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com.
The Toronto Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
HELIUS CONTACTS:
Investor Relations:
Josh Berg, 415-205-7891
[email protected]
Media Contact:
Becky Kern, 914-772-2310
[email protected]
